Cyprium Receives FDA Approval, $129mln in Milestones, and PRV Voucher.

• FDA approves ZYCUBO for Menkes disease in pediatric patients. • Rare Pediatric Disease Priority Review Voucher granted to Sentynl Therapeutics. • Voucher to be transferred to Cyprium Therapeutics. • Cyprium eligible for tiered royalties and up to $129 million in milestones. • Sentynl Therapeutics assumed full responsibility for CUTX-101 development and commercialization.